The hits keep on coming for pharmaceutical giant GlaxoSmithKline.

GSK confirmed today that is facing a criminal investigation into possible violations of the Foreign Corrupt Practices Act and the U.K. Bribery Act. The investigation was announced the same week that the company became embroiled in a similar corruption probe for improper payments made in Iraq. The company also faces an ongoing investigation into possible bribery payments made in China.

The latest bribery probe centers on allegations that a GSK regional manager bribed eleven doctors in Poland from 2010 to 2012 to promote the company's asthma drug Seretide, BBC Panorama reported.

On April 14, GSK responded in a prepared statement that it launched an investigation in 2011 when it became aware of the allegations. “The investigation found evidence of inappropriate communication in contravention of GSK policy by a single employee,” the company stated.

“The employee concerned was reprimanded and disciplined in 2011,” GSK stated. “We continue to investigate these matters.”

More Probes

Since July 2013, GSK also has been embroiled in another corruption probe over allegations that senior management at GSK's China operations made bribery payments in the form of cash payments, lavish dinners, and all-expenses-paid trips to doctors in China in exchange for prescribing Botox. That investigation remains ongoing.

In addition, GSK said last week that launched an internal investigation into potential violations of the FCPA for alleged bribery payments made to doctors in Iraq. GSK is investigating claims into whether some of its employees hired government-employed doctors and pharmacists in Iraq as paid sales representatives in exchange for promoting and prescribing its drugs.

In response to the ongoing investigations, GSK said that “there is a need to modernize interactions between the pharmaceutical industry and healthcare professionals…to eliminate even a perception of a conflict of interest.”  

For its part, GSK said it continues to make “fundamental changes” to its operations, such as opening up access to our clinical trial data, changing how we pay our sales representatives, and stopping payments to healthcare professionals for speaking engagements and for attendance at medical conferences.”